JP2013509433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509433A5 JP2013509433A5 JP2012537128A JP2012537128A JP2013509433A5 JP 2013509433 A5 JP2013509433 A5 JP 2013509433A5 JP 2012537128 A JP2012537128 A JP 2012537128A JP 2012537128 A JP2012537128 A JP 2012537128A JP 2013509433 A5 JP2013509433 A5 JP 2013509433A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- compound
- pharmaceutically acceptable
- acceptable salt
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 208000036142 Viral infection Diseases 0.000 claims 9
- 230000009385 viral infection Effects 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 6
- 241000701460 JC polyomavirus Species 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 6
- 230000003442 weekly effect Effects 0.000 claims 6
- 241000701022 Cytomegalovirus Species 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 241000701161 unidentified adenovirus Species 0.000 claims 5
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 4
- 241000701027 Human herpesvirus 6 Species 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 241000829111 Human polyomavirus 1 Species 0.000 claims 4
- 241000700647 Variola virus Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 206010011793 Cystitis haemorrhagic Diseases 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 201000003740 cowpox Diseases 0.000 claims 2
- 201000002802 hemorrhagic cystitis Diseases 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 238000007917 intracranial administration Methods 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims 2
- 208000005871 monkeypox Diseases 0.000 claims 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 230000029812 viral genome replication Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960005102 foscarnet Drugs 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 229940093257 valacyclovir Drugs 0.000 claims 1
- 0 C*I*P(C*[C@@](CN(C=CC(*)=N1)C1=O)COC)(O)=[U] Chemical compound C*I*P(C*[C@@](CN(C=CC(*)=N1)C1=O)COC)(O)=[U] 0.000 description 1
Applications Claiming Priority (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25670109P | 2009-10-30 | 2009-10-30 | |
| US61/256,701 | 2009-10-30 | ||
| US32699110P | 2010-04-22 | 2010-04-22 | |
| US32698610P | 2010-04-22 | 2010-04-22 | |
| US32698210P | 2010-04-22 | 2010-04-22 | |
| US32698910P | 2010-04-22 | 2010-04-22 | |
| US61/326,991 | 2010-04-22 | ||
| US61/326,986 | 2010-04-22 | ||
| US61/326,989 | 2010-04-22 | ||
| US61/326,982 | 2010-04-22 | ||
| US32747410P | 2010-04-23 | 2010-04-23 | |
| US61/327,474 | 2010-04-23 | ||
| US32791410P | 2010-04-26 | 2010-04-26 | |
| US61/327,914 | 2010-04-26 | ||
| US32849110P | 2010-04-27 | 2010-04-27 | |
| US61/328,491 | 2010-04-27 | ||
| US33062410P | 2010-05-03 | 2010-05-03 | |
| US61/330,624 | 2010-05-03 | ||
| US33170410P | 2010-05-05 | 2010-05-05 | |
| US61/331,704 | 2010-05-05 | ||
| US35543010P | 2010-06-16 | 2010-06-16 | |
| US61/355,430 | 2010-06-16 | ||
| US40508010P | 2010-10-20 | 2010-10-20 | |
| US40507510P | 2010-10-20 | 2010-10-20 | |
| US40507310P | 2010-10-20 | 2010-10-20 | |
| US40508410P | 2010-10-20 | 2010-10-20 | |
| US61/405,080 | 2010-10-20 | ||
| US61/405,084 | 2010-10-20 | ||
| US61/405,075 | 2010-10-20 | ||
| US61/405,073 | 2010-10-20 | ||
| PCT/US2010/054779 WO2011053812A1 (en) | 2009-10-30 | 2010-10-29 | Methods of treating viral associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013509433A JP2013509433A (ja) | 2013-03-14 |
| JP2013509433A5 true JP2013509433A5 (https=) | 2013-12-19 |
Family
ID=43922582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537128A Pending JP2013509433A (ja) | 2009-10-30 | 2010-10-29 | ウイルス関連疾患を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130072458A1 (https=) |
| EP (1) | EP2493479A4 (https=) |
| JP (1) | JP2013509433A (https=) |
| AU (1) | AU2010313273B2 (https=) |
| CA (1) | CA2779473C (https=) |
| WO (1) | WO2011053812A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642577B2 (en) | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| ES2572631T3 (es) | 2008-01-25 | 2016-06-01 | Chimerix, Inc. | Métodos de tratamiento de infecciones virales |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
| CA2797601A1 (en) | 2010-04-26 | 2011-11-10 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
| WO2012031045A2 (en) * | 2010-08-31 | 2012-03-08 | Chimerix, Inc. | Phosphonate ester derivatives and methods of synthesis thereof |
| US20140303092A1 (en) * | 2011-10-26 | 2014-10-09 | Chimerix, Inc | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| EP3578563B1 (en) | 2011-12-22 | 2021-04-14 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
| WO2013163509A1 (en) * | 2012-04-27 | 2013-10-31 | Chimerix, Inc. | A method of mitigating virus associated end-organ damage |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| US9526729B2 (en) * | 2013-01-29 | 2016-12-27 | Hsiao Lily Yu | Medicament for treating peripheral neuropathies |
| SG10201800188SA (en) | 2013-03-15 | 2018-02-27 | Univ California | Acyclic nucleoside phosphonate diesters |
| US8962829B1 (en) | 2013-11-15 | 2015-02-24 | Chimerix, Inc. | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
| CN111808136B (zh) | 2014-09-15 | 2024-06-11 | 加利福尼亚大学董事会 | 核苷酸类似物 |
| US10160778B2 (en) | 2014-10-27 | 2018-12-25 | Concert Pharmaceuticals, Inc. | Pyrimidine phosphonic acid esters |
| EP3350191B9 (en) | 2015-09-15 | 2021-12-22 | The Regents of the University of California | Nucleotide analogs |
| WO2017196990A1 (en) * | 2016-05-12 | 2017-11-16 | Contravir Pharmaceuticals, Inc. | Methods of treating hepatitis b infections and related dosage regimes |
| AU2017290703B2 (en) | 2016-06-28 | 2023-03-30 | Emergent Biodefense Operations Lansing Llc | Formulations of brincidofovir |
| WO2018156879A1 (en) * | 2017-02-23 | 2018-08-30 | Chimerix, Inc. | Treatment of adenovirus with brincidofovir |
| WO2020138067A1 (ja) * | 2018-12-25 | 2020-07-02 | 富士フイルム富山化学株式会社 | ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるｒｎａウイルス感染症治療剤 |
| KR20210145207A (ko) * | 2019-03-29 | 2021-12-01 | 에보니크 오퍼레이션즈 게엠베하 | 헤르페스비리다에에 의해 유발된 바이러스 감염의 예방 및/또는 치료에 사용하기 위한 베리 추출물을 함유하는 제제 |
| CN117285565A (zh) * | 2022-06-24 | 2023-12-26 | 润佳（苏州）医药科技有限公司 | 核苷类似物及其医药用途 |
| KR20250052378A (ko) | 2022-07-21 | 2025-04-18 | 안티바 바이오사이언시즈, 인크. | Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태 |
| JP7417339B1 (ja) | 2023-08-07 | 2024-01-18 | シンバイオ製薬株式会社 | アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605602B1 (en) * | 2001-09-28 | 2003-08-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of treating BK virus nephropathy |
| WO2003091264A2 (en) * | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
| US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
| EP1802287A2 (en) * | 2004-09-27 | 2007-07-04 | Sigmoid Biotechnologies Limited | Minicapsule formulations |
| US8642577B2 (en) * | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| PL2308514T3 (pl) * | 2007-03-23 | 2013-11-29 | To Bbb Holding B V | Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg |
| AU2008246195B2 (en) * | 2007-04-27 | 2014-06-05 | Emergent Biodefence Operations Lansing Llc | Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates |
| CA2770282A1 (en) * | 2009-08-03 | 2011-02-10 | Chimerix, Inc. | Composition and methods of treating viral infections and viral induced tumors |
| US20110263536A1 (en) * | 2010-04-22 | 2011-10-27 | Chimerix, Inc. | Methods of Treating Orthopox Virus Infections and Associated Diseases |
-
2010
- 2010-10-29 CA CA2779473A patent/CA2779473C/en active Active
- 2010-10-29 EP EP10827544.7A patent/EP2493479A4/en not_active Ceased
- 2010-10-29 JP JP2012537128A patent/JP2013509433A/ja active Pending
- 2010-10-29 WO PCT/US2010/054779 patent/WO2011053812A1/en not_active Ceased
- 2010-10-29 US US13/504,785 patent/US20130072458A1/en not_active Abandoned
- 2010-10-29 AU AU2010313273A patent/AU2010313273B2/en active Active
-
2014
- 2014-11-14 US US14/542,295 patent/US20150141375A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509433A5 (https=) | ||
| JP2010525063A5 (https=) | ||
| Kim et al. | Coinfection with HIV-1 and HCV—a one-two punch | |
| De Clercq | Antivirals: past, present and future | |
| RU2015141024A (ru) | Производные эфиров фосфоновых кислот и способы их синтеза | |
| De Clercq et al. | Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy) alkoxy]-2, 4-diaminopyrimidines | |
| JP2013231058A5 (https=) | ||
| Slots | Oral viral infections of adults. | |
| de Clercq | Milestones in the discovery of antiviral agents: nucleosides and nucleotides | |
| Slifkin et al. | Viral prophylaxis in organ transplant patients | |
| JP2016515128A5 (https=) | ||
| JP2015038149A5 (https=) | ||
| Speth et al. | HIV-infection of the central nervous system: the tightrope walk of innate immunity | |
| HRP20151357T1 (hr) | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa | |
| JP2013503882A5 (https=) | ||
| JP2014526508A5 (https=) | ||
| WO2016086153A2 (en) | Use of tetrahydro!ndazolylbeimzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids) | |
| AU2016271995A1 (en) | Antiviral composition | |
| Amarapurkar et al. | Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection | |
| MX2011010049A (es) | Proceso para la preparacion de un compuesto antiviral. | |
| WO2020055368A2 (en) | Usage of terpenic coumarin derived molecules in treating viral diseases | |
| Actor | Clinical virology | |
| Bourliere et al. | HBsAg clearance after addition of 48 weeks of PEGIFN in HBeAg negative CHB patients on Nucleos (t) ide therapy with undetectable HBV DNA for at least one year: a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study: preliminary findings: 1863 | |
| JP2002531495A5 (https=) | ||
| Samant et al. | Cytokine Response Against Major Human Viral Infections |